ABSTRACT Thirty five previously untreated patients with small cell lung cancer older than 70 years, were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxicity. It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer.
Introduction

Methods
For most patients with small cell lung cancer the introduction of combination chemotherapy has considerably prolonged median survival' in addition to improving the quality of life. For elderly patients, however, aggressive combination chemotherapy is often associated with life threatening toxicity, especially myelosuppression.2 For these reasons elderly patients often have been and still are excluded from most clinical phase II trials. Treatment of these patients, however, is often indicated.
One of the most active agents for small cell lung cancer is the epipodophyllotoxin derivative etoposide (VP 16-213), which has been associated with response rates of up to 65% when used as a single agent in previously untreated patients.3 It is associated with relatively mild toxicity, mainly myelosuppression. Etoposide has clearcut dose and schedule related activity; a five day regimen has been shown to be superior to a single infusion of the same total dose in patients with small cell lung cancer.4
Etoposide is available for oral administration, after which bioavailability is about half, though there is considerable interpatient and intrapatient variability. Smit, Carney, Harford, Sleijfer, Postmus
All patients experienced alopecia, usually complete. Gastrointestinal toxicity was easy to handle. Only a few patients needed symptomatic treatment.
Discussion
The proportion of patients with small cell lung cancer who are over 70 years is not clear. In a report by Kreyborg in 1969' only 4% of the patients with small cell lung cancer were over 70, though in a recent large American survey 26% were over 70.8 In our institutions about 15% of patients presenting with small cell lung cancer are older than 70. Concerns about increased toxicity of combination chemotherapy in elderly patients may be the reason why physicians tend to avoid this approach. 9 Various reports are available on palliative treatment of elderly patients or those with a poor prognosis (by virtue of their performance score or extent of disease). In two studies using a two drug regimen including etoposide'°" response rates were around 70%. The results for our patients with extensive disease-a 70% response rate and a median survival of nine monthsare in agreement with the results of these studies. For the patients with limited disease the median survival was somewhat longer than in the study ofAllan et al'0: 16 versus 12-5 months. We had less toxicity and no drug related deaths, and apart from alopecia no important non-haematological side effects. In these two studies the other drug in the combination, vindesine or vincristine, probably contributed to the observed toxicity. A major advantage ofour treatment is that it may be given on an outpatient basis with minimal investigations and hospital visits.
The median survival for the patients in this study is very reasonable both for those with extensive disease (nine months) and for those with limited disease (16 months). Though some series report better survival for the latter group, this might be only at the cost of more treatment related toxicity. Certainly for elderly patients, who are less able to tolerate or survive standard chemotherapy regimens, a shorter median survival with the alleviation of symptoms may be considered as an acceptable goal.
We conclude from our data that orally administered etoposide at a dose of 800 mg/m2 divided over five consecutive days is a well tolerated and effective regimen for palliation in elderly patients with small cell lung cancer. 
